These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8328779)

  • 1. Inactivation of rifampin by Nocardia brasiliensis.
    Yazawa K; Mikami Y; Maeda A; Akao M; Morisaki N; Iwasaki S
    Antimicrob Agents Chemother; 1993 Jun; 37(6):1313-7. PubMed ID: 8328779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorylative inactivation of rifampicin by Nocardia otitidiscaviarum.
    Yazawa K; Mikami Y; Maeda A; Morisaki N; Iwasaki S
    J Antimicrob Chemother; 1994 Jun; 33(6):1127-35. PubMed ID: 7928806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivated products of rifampicin by pathogenic Nocardia spp.: structures of glycosylated and phosphorylated metabolites of rifampicin and 3-formylrifamycin SV.
    Morisaki N; Iwasaki S; Yazawa K; Mikami Y; Maeda A
    J Antibiot (Tokyo); 1993 Oct; 46(10):1605-10. PubMed ID: 8244890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ribosylation by mycobacterial strains as a new mechanism of rifampin inactivation.
    Dabbs ER; Yazawa K; Mikami Y; Miyaji M; Morisaki N; Iwasaki S; Furihata K
    Antimicrob Agents Chemother; 1995 Apr; 39(4):1007-9. PubMed ID: 7785970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivation of kanamycin A by phosphorylation in pathogenic Nocardia.
    Yazawa K; Mikami Y; Maeda A; Kudo T; Suzuki K; Saito N; Kubo A
    Microbiol Immunol; 1991; 35(1):39-48. PubMed ID: 1651439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivation of the macrolide antibiotics erythromycin, midecamycin, and rokitamycin by pathogenic Nocardia species.
    Yazawa K; Mikami Y; Sakamoto T; Ueno Y; Morisaki N; Iwasaki S; Furihata K
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2197-9. PubMed ID: 7811046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycosylative inactivation of chalcomycin and tylosin by a clinically isolated Nocardia asteroides strain.
    Morisaki N; Hashimoto Y; Furihata K; Yazawa K; Tamura M; Mikami Y
    J Antibiot (Tokyo); 2001 Feb; 54(2):157-65. PubMed ID: 11302489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transvalencin Z, a new antimicrobial compound with salicylic acid residue from Nocardia transvalensis IFM 10065.
    Mukai A; Fukai T; Matsumoto Y; Ishikawa J; Hoshino Y; Yazawa K; Harada K; Mikami Y
    J Antibiot (Tokyo); 2006 Jun; 59(6):366-9. PubMed ID: 16915823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity of various species of Nocardia to rifampin in vitro.
    Tanzil HO; Chatim A; Utomo RR; Harun H
    Am Rev Respir Dis; 1972 Mar; 105(3):455-6. PubMed ID: 5011675
    [No Abstract]   [Full Text] [Related]  

  • 10. Nocardicyclins A and B: new anthracycline antibiotics produced by Nocardia pseudobrasiliensis.
    Tanaka Y; Gräfe U; Yazawa K; Mikami Y; Ritzau M
    J Antibiot (Tokyo); 1997 Oct; 50(10):822-7. PubMed ID: 9402986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three new reduced anthracycline related compounds from pathogenic Nocardia brasiliensis.
    Maeda A; Nagai H; Yazawa K; Tanaka Y; Imai T; Mikami Y; Kuramochi T; Yamazaki C
    J Antibiot (Tokyo); 1994 Sep; 47(9):976-81. PubMed ID: 7928699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biotransformation of bile acids by pathogenic actinomycetes Nocardia otitidiscaviarum and Amycolatopsis sp. strains.
    Mukai A; Yazawa K; Mikami Y; Harada K; Gräfe U
    J Antibiot (Tokyo); 2005 May; 58(5):356-60. PubMed ID: 16060390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbial glycosylation of erythromycin A.
    Kuo MS; Chirby DG; Argoudelis AD; Cialdella JI; Coats JH; Marshall VP
    Antimicrob Agents Chemother; 1989 Dec; 33(12):2089-91. PubMed ID: 2619274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure determination of ribosylated rifampicin and its derivative: new inactivated metabolites of rifampicin by mycobacterial strains.
    Morisaki N; Kobayashi H; Iwasaki S; Furihata K; Dabbs ER; Yazawa K; Mikami Y
    J Antibiot (Tokyo); 1995 Nov; 48(11):1299-303. PubMed ID: 8557572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production of erythromycin E by pathogenic Nocardia brasiliensis.
    Mikami Y; Yazawa K; Nemoto A; Komaki H; Tanaka Y; Gräfe U
    J Antibiot (Tokyo); 1999 Feb; 52(2):201-2. PubMed ID: 10344579
    [No Abstract]   [Full Text] [Related]  

  • 16. Brasilicardin A, a new terpenoid antibiotic from pathogenic Nocardia brasiliensis: fermentation, isolation and biological activity.
    Komaki H; Nemoto A; Tanaka Y; Takagi H; Yazawa K; Mikami Y; Shigemori H; Kobayashi J; Ando A; Nagata Y
    J Antibiot (Tokyo); 1999 Jan; 52(1):13-9. PubMed ID: 10092191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonistic Activity of Nocardia brasiliensis PTCC 1422 Against Isolated Enterobacteriaceae from Urinary Tract Infections.
    Jalali HK; Salamatzadeh A; Jalali AK; Kashani HH; Asbchin SA; Issazadeh K
    Probiotics Antimicrob Proteins; 2016 Mar; 8(1):41-5. PubMed ID: 26920557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activities of new antimicrobials against Nocardia brasiliensis.
    Vera-Cabrera L; Gonzalez E; Choi SH; Welsh O
    Antimicrob Agents Chemother; 2004 Feb; 48(2):602-4. PubMed ID: 14742215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro activity of flomoxef, a new oxacephem group antibiotic, against Nocardia in comparison with other cephalosporins.
    Yazawa K; Mikami Y; Uno J; Otozai K; Arai T
    J Antimicrob Chemother; 1989 Dec; 24(6):921-5. PubMed ID: 2621177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro antimicrobial susceptibilities of Nocardia species.
    Khardori N; Shawar R; Gupta R; Rosenbaum B; Rolston K
    Antimicrob Agents Chemother; 1993 Apr; 37(4):882-4. PubMed ID: 8494385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.